X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Tesamorelin F8
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F8
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rifaximin,Lactulose
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
In the study, the treatment arm evaluating 40 mg BID of rifaximin SSD IR plus standard of care therapy met its primary endpoint of time to resolution of OHE.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
